{"id":{"repo_id":"york","oai_identifier":"oai:yorkspace.library.yorku.ca:10315/42749"},"canonical_url":"https://search.dev.ndltd.org/etd/york/oai:yorkspace.library.yorku.ca:10315/42749","repository":{"repo_id":"york","name":"York University","base_url":"https://yorkspace.library.yorku.ca/oai/request"},"display":{"title":"Effects Of Sustained Release Somatostatin Type 2 Antagonism On Glucagon Counterregulation And Glycemia In Type 2 Diabetic Rate Model","abstract":"This thesis examined whether a novel somatostatin receptor 2 antagonist (SSTR2a), ZT-01, could enhance endogenous glucagon secretion and protect against hypoglycemia in a rat model of type 2 diabetes (T2D). Male Sprague Dawley rats were placed on a high-fat diet and injected with streptozotocin to induce T2D. The rats were then chronically treated with varying doses of ZT-01 or vehicle using implanted mini-osmotic pumps. While ZT-01 did not significantly affect basal glucose levels or oral glucose tolerance, it tended to increase baseline glucagon levels and the glucagon response to insulin-induced hypoglycemia, though the effects were small. Overall, sustained exposure to SSTR2a modestly improved the glucose and glucagon response to insulin-induced hypoglycemia in this T2D model, suggesting the potential for this approach to prevent hypoglycemia in insulin-requiring T2D.","abstract_html":"This thesis examined whether a novel somatostatin receptor 2 antagonist (SSTR2a), ZT-01, could enhance endogenous glucagon secretion and protect against hypoglycemia in a rat model of type 2 diabetes (T2D). Male Sprague Dawley rats were placed on a high-fat diet and injected with streptozotocin to induce T2D. The rats were then chronically treated with varying doses of ZT-01 or vehicle using implanted mini-osmotic pumps. While ZT-01 did not significantly affect basal glucose levels or oral glucose tolerance, it tended to increase baseline glucagon levels and the glucagon response to insulin-induced hypoglycemia, though the effects were small. Overall, sustained exposure to SSTR2a modestly improved the glucose and glucagon response to insulin-induced hypoglycemia in this T2D model, suggesting the potential for this approach to prevent hypoglycemia in insulin-requiring T2D.","abstract_has_math":false,"creators":["Aleali, Nadia"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":["Riddell, Michael C."],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025-04-10","date_published":"2025-04-10","updated_at":"2026-07-24T06:34:03Z","subjects":[],"languages":["en"],"rights":["Author owns copyright, except where explicitly noted. Please contact the author directly with licensing requests."],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/10315/42749","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Riddell, Michael C."]},{"key":"dc:creator","label":"Author","values":["Aleali, Nadia"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2025-04-10T10:42:14Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2025-04-10T10:42:14Z"]},{"key":"dc:date.issued","label":"Date","values":["2025-04-10"]},{"key":"dc:type","label":"Dc Type","values":["Electronic Thesis or Dissertation"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language","label":"Dc Language","values":["en"]},{"key":"dc:rights","label":"Dc Rights","values":["Author owns copyright, except where explicitly noted. Please contact the author directly with licensing requests."]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/10315/42749"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["This thesis examined whether a novel somatostatin receptor 2 antagonist (SSTR2a), ZT-01, could enhance endogenous glucagon secretion and protect against hypoglycemia in a rat model of type 2 diabetes (T2D). Male Sprague Dawley rats were placed on a high-fat diet and injected with streptozotocin to induce T2D. The rats were then chronically treated with varying doses of ZT-01 or vehicle using implanted mini-osmotic pumps. While ZT-01 did not significantly affect basal glucose levels or oral glucose tolerance, it tended to increase baseline glucagon levels and the glucagon response to insulin-induced hypoglycemia, though the effects were small. Overall, sustained exposure to SSTR2a modestly improved the glucose and glucagon response to insulin-induced hypoglycemia in this T2D model, suggesting the potential for this approach to prevent hypoglycemia in insulin-requiring T2D."]},{"key":"dc:title","label":"Title","values":["Effects Of Sustained Release Somatostatin Type 2 Antagonism On Glucagon Counterregulation And Glycemia In Type 2 Diabetic Rate Model"]}]}],"canonical_facts":{"dc:contributor.advisor":["Riddell, Michael C."],"dc:creator":["Aleali, Nadia"],"dc:date.accessioned":["2025-04-10T10:42:14Z"],"dc:date.available":["2025-04-10T10:42:14Z"],"dc:date.issued":["2025-04-10"],"dc:description.abstract":["This thesis examined whether a novel somatostatin receptor 2 antagonist (SSTR2a), ZT-01, could enhance endogenous glucagon secretion and protect against hypoglycemia in a rat model of type 2 diabetes (T2D). Male Sprague Dawley rats were placed on a high-fat diet and injected with streptozotocin to induce T2D. The rats were then chronically treated with varying doses of ZT-01 or vehicle using implanted mini-osmotic pumps. While ZT-01 did not significantly affect basal glucose levels or oral glucose tolerance, it tended to increase baseline glucagon levels and the glucagon response to insulin-induced hypoglycemia, though the effects were small. Overall, sustained exposure to SSTR2a modestly improved the glucose and glucagon response to insulin-induced hypoglycemia in this T2D model, suggesting the potential for this approach to prevent hypoglycemia in insulin-requiring T2D."],"dc:identifier.uri":["https://hdl.handle.net/10315/42749"],"dc:language":["en"],"dc:rights":["Author owns copyright, except where explicitly noted. Please contact the author directly with licensing requests."],"dc:title":["Effects Of Sustained Release Somatostatin Type 2 Antagonism On Glucagon Counterregulation And Glycemia In Type 2 Diabetic Rate Model"],"dc:type":["Electronic Thesis or Dissertation"]},"updated_at":"2026-07-24T06:34:03Z"}